Here are 1-3 brief analogies for Aethlon Medical (AEMD):

• They're like a highly specialized Fresenius Medical Care, but their device purifies blood by specifically removing cancer-promoting exosomes and dangerous viruses, rather than kidney waste.

• Imagine an innovative medical device company, similar to Intuitive Surgical, but instead of robotic surgery systems, Aethlon develops a device that cleans your blood to fight life-threatening diseases like cancer and viral infections.

• They are also developing advanced diagnostic tests, somewhat like Exact Sciences (makers of Cologuard), but for difficult-to-diagnose conditions such as Chronic Traumatic Encephalopathy (CTE) using exosomal biomarkers.

```html

• Aethlon Hemopurifier: A clinical-stage immunotherapeutic device designed to remove tumor-derived exosomes and life-threatening viruses from the human circulatory system.
• TauSome: An exosomal biomarker candidate being developed to diagnose chronic traumatic encephalopathy in living individuals.

```

null

null

James B. Frakes, Chief Executive Officer and Chief Financial Officer

Mr. Frakes was appointed permanent Chief Executive Officer on October 3, 2024, after serving as Interim CEO since November 7, 2023, and continues to fulfill his responsibilities as Chief Financial Officer. He joined Aethlon Medical in January 2008 and became Chief Financial Officer in September 2010. Mr. Frakes has 27 years of CFO-level financial responsibility for publicly traded companies. His background includes previous CFO positions at Left Behind Games Inc. and NTN Buzztime, Inc., and he served as CFO of four public companies over a sixteen-year period prior to joining Aethlon Medical. He has specific knowledge and experience in equity (IPO, follow-on public offerings, and private placements) and debt transactions, acquisitions, public reporting, and Sarbanes-Oxley section 404 internal control requirements. Mr. Frakes holds an MBA from the University of Southern California and a BA with Honors from Stanford University.

Steven LaRosa, M.D., Chief Medical Officer

Dr. LaRosa joined Aethlon Medical in January 2021. Prior to Aethlon, he served as the Vice President of Clinical Development of Entasis Therapeutics, a spin-out of AstraZeneca, where he was responsible for the clinical development of multiple programs, including two in Phase III clinical trials. He was also an Attending Physician and Antimicrobial Stewardship Director at Beverly Hospital, a member of Beth Israel Lahey Health, and an Assistant Professor of Medicine at Brown Medical School and Attending Physician at Rhode Island Hospital. Dr. LaRosa was a co-founder and Director of the Ocean State Clinical Coordinating Center (OSCCC), an academic CRO. He previously served as a Clinical Research Physician for Eli Lilly and Company, where he led the Phase III clinical trial of recombinant human activated Protein C (Xigris), which was FDA approved for sepsis. He received his M.D. from Boston University School of Medicine.

Michele Bombardiere, Vice President, Controller

Ms. Bombardiere has held senior and executive positions, excelling in financial analysis, process streamlining, driving operational efficiency, and managing cross-functional teams. Her career includes leading critical functions beyond finance and accounting, such as operations, technology, and customer engagement, and she has been instrumental in securing funding, supporting strategic acquisitions, and improving business results.

John Nguyen, Vice President of Manufacturing

Mr. Nguyen is an operations and technical leader with 25 years of experience in biotech and life sciences, focusing on the development and manufacturing of medical devices. He has experience in building scalable team structures, managing product lines, and overseeing high-profile projects with a focus on process improvements and cost savings. Before joining Aethlon Medical, he was Director of Technical Operations and then Vice President of Operations at Nexus Dx, where he was responsible for new product development and manufacturing transfer. Mr. Nguyen holds a Bachelor of Arts in Biology from the University of San Diego.

The key risks to Aethlon Medical (AEMD) are primarily centered around its financial viability, the complex nature of clinical development and regulatory approvals for its investigational devices, and challenges related to market acceptance and competition. Here are the key risks, ordered from most significant to less significant:

1. Financial Health and Funding

Aethlon Medical faces substantial financial and operational risks that could impact its future viability. The company has reported ongoing losses and deeply negative operating and net margins, with zero revenue growth over the past three years. It is quickly burning through cash and needs additional financing to support its operations and advance its clinical trials. The necessity for further funding carries the risk of diluting existing stockholders' ownership. The company is actively exploring strategic opportunities and partnerships to address these financial challenges.

2. Clinical Development and Regulatory Approval

As a clinical-stage medical technology company, Aethlon Medical's primary products, such as the Aethlon Hemopurifier and TauSome, are investigational devices whose safety and effectiveness have not yet been established. The company faces significant risks associated with the outcomes of its clinical trials, including potential delays or failures. Navigating the complex and stringent regulatory landscape, including approvals from bodies like the U.S. Food and Drug Administration (FDA) and international ethics boards, represents a major hurdle for market access.

3. Market Acceptance and Competition

Even if its products successfully navigate clinical trials and receive regulatory approval, Aethlon Medical faces risks related to market acceptance and intense competition within the healthcare sector. There is also a potential risk of obsolescence for its Hemopurifier technology. Furthermore, the company has limited experience in large-scale contracts and relies on third-party suppliers for critical materials, which could pose operational challenges. The stock also exhibits high volatility, and there is a risk of delisting from the Nasdaq Capital Market.

null

Addressable Markets for Aethlon Medical's Products

Aethlon Medical, Inc. (AEMD) is developing the Aethlon Hemopurifier and TauSome, targeting significant global addressable markets.

Aethlon Hemopurifier

The Aethlon Hemopurifier, an immunotherapeutic device designed to remove tumor-derived exosomes and life-threatening viruses, addresses a substantial market. While Aethlon Medical's CEO has described the oncology market as "huge," referencing Keytruda's $25 billion annual sales, more specific market sizing for exosome therapeutics is available.

• The global exosome therapeutics market size is estimated at USD 928.93 thousand in 2025 and is projected to increase to approximately USD 4,020.75 thousand by 2034, with a compound annual growth rate (CAGR) of 17.68% from 2025 to 2034.
• Other estimates place the global exosome therapy market at USD 32 million in 2029, growing to USD 382 million by 2035 and USD 1,405 million by 2040, at a CAGR of 41.1%.
• The global exosome diagnostic and therapeutic market was valued at $224.34 million in 2020 and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030.
• North America is identified as the largest market for exosome therapeutics, holding approximately 45% of the global share.

TauSome

TauSome, an exosomal biomarker candidate for diagnosing chronic traumatic encephalopathy (CTE), targets a growing global market:

• The global Chronic Traumatic Encephalopathy (CTE) market was estimated at USD 2.3 billion in 2023 and is expected to reach around USD 4.3 billion by 2032, with a CAGR of approximately 7.1% from 2024 to 2032.
• Another report estimates the global CTE market size to grow from $1.51 billion in 2025 to $1.65 billion in 2026 at an 8.7% CAGR, further expanding to $2.27 billion in 2030 at an 8.4% CAGR.
• The CTE market is also estimated to be valued at USD 1021.2 million in 2025 and is expected to reach USD 1597.4 million by 2032, growing at a CAGR of 6.6% from 2025 to 2032.
• The global Chronic Traumatic Encephalopathy (CTE) Market is forecast to grow from USD 1.2 billion in 2024 to USD 2.1 billion by 2030, registering a CAGR of 9.1%.
• North America was the largest region in the chronic traumatic encephalopathy market in 2025 and is expected to maintain its dominance. Specifically, the USA Chronic Traumatic Encephalopathy (CTE) Market is estimated at USD 0.50 billion in 2024 and is projected to reach approximately USD 0.80 billion by 2030 with an 8.0% CAGR.

Aethlon Medical (NASDAQ: AEMD) is a medical technology company focused on developing its Hemopurifier device and TauSome diagnostic candidate. Given its clinical-stage nature, the expected drivers of future revenue growth over the next 2-3 years are intrinsically linked to the successful advancement and commercialization of its pipeline products.

1. Commercialization of the Hemopurifier in Oncology: A primary driver of future revenue growth is the successful completion of clinical trials, regulatory approval, and subsequent commercialization of the Aethlon Hemopurifier for oncology applications. The device is currently in clinical trials in Australia for solid tumor patients undergoing anti-PD-1 therapy, with the aim of removing tumor-derived exosomes that can promote immune suppression and metastasis, potentially enhancing the efficacy of immunotherapies. Successful trials and regulatory clearance (e.g., FDA in the U.S. and TGA in Australia) would enable market entry.

2. Expansion of Hemopurifier Applications to Infectious Diseases and Organ Transplantation: Beyond oncology, the Hemopurifier is being developed for the treatment of life-threatening viral infections and for use in organ transplantation. The company has secured patents related to Long COVID treatment and COVID-19-associated coagulopathy, indicating potential future applications in these areas. Positive clinical outcomes and regulatory approvals for these additional indications would broaden the device's market reach and create new revenue streams.

3. Development and Commercialization of TauSome for Chronic Traumatic Encephalopathy (CTE) Diagnosis: Aethlon's subsidiary, Exosome Sciences, is advancing TauSome as an exosomal biomarker for the diagnosis of Chronic Traumatic Encephalopathy (CTE) in living individuals. The publication of preliminary findings for this blood-based test is a step toward its potential commercialization. The successful validation and market introduction of this diagnostic tool would address a significant unmet medical need and contribute to future revenue.

4. Strategic Partnerships and Acquisitions: Aethlon Medical is actively exploring strategic opportunities, including potential partnerships and acquisitions, with the assistance of Maxim Group LLC. Such collaborations or an eventual acquisition could provide capital, accelerate product development, enhance market access, or lead to direct revenue generation for the company or its shareholders.

Share Issuance

• In February 2026, Aethlon Medical's stockholders approved a significant increase in the authorized common stock from 6 million to 100 million shares.
• Shareholders also approved the potential issuance of up to approximately 2 million shares related to warrants from a December 2025 Securities Purchase Agreement and a Warrant Inducement Agreement.
• The company completed a private placement in December 2025, generating approximately $3.3 million in gross proceeds through the sale of common stock and warrants to a single institutional investor.

Inbound Investments

• Aethlon Medical secured approximately $3.3 million in gross proceeds in December 2025 from a private placement and a warrant inducement agreement with a single institutional investor.
• In March 2026, Aethlon Medical engaged Maxim Group LLC to evaluate strategic opportunities, including potential partnerships, mergers, or acquisitions, following preliminary inbound interest.

Capital Expenditures

• Aethlon Medical maintained disciplined cost controls and operational efficiency, leading to lower year-to-date operating expenses for fiscal year 2026.
• Consolidated operating expenses for the nine months ended December 31, 2025, were approximately $5.36 million, marking a decrease of about $1.98 million, or 26.9%, compared to the same period in 2024.